Labcorp said Wednesday it has debuted a test designed to identify the presence or absence of a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease.
The test focuses on phosphorylated tau 217 (pTau217). The test also assists in the monitoring of patients undergoing treatment with new Alzheimer's disease therapies.
The pTau217 marker has been used in Alzheimer's drug trials to monitor patients on anti-amyloid therapy.
An estimated 6.7 million Americans are currently living with Alzheimer's disease, a figure projected to more than double to 13.8 million by 2060.